TrialCancer2022

JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.

Suresh S Ramalingam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.